<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Procedures for UK Paediatric Investigation Plan (PIPs) from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">The process for applicants applying for a Paediatric Investigation Plan (PIP) waiver from 1 January 2021.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
    <br></br>Last updated 27 October 2020
      — <a href="#history" class="app-c-published-dates__history-link govuk-link">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region" lang="en">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/government/publications/legal-requirements-for-childrens-medicines/legal-requirements-for-childrens-medicines" data-track-label="Legal requirements for children's medicines" class="app-c-header-notice__link" href="/government/publications/legal-requirements-for-childrens-medicines/legal-requirements-for-childrens-medicines">Legal requirements for children's medicines</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " aria-label="Contents" role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">
        Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#general-approach-to-uk-paediatric-investigation-plans" data-track-options="{"dimension29":"General approach to UK Paediatric Investigation Plans"}" href="#general-approach-to-uk-paediatric-investigation-plans">General approach to UK Paediatric Investigation Plans</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#section-one" data-track-options="{"dimension29":"Section 1: PIP submissions"}" href="#section-one">Section 1: PIP submissions</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#section-2-pip-modifications" data-track-options="{"dimension29":"Section 2: PIP Modifications"}" href="#section-2-pip-modifications">Section 2: PIP Modifications</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 4" data-track-label="#section-3-class-waivers" data-track-options="{"dimension29":"Section 3: Class Waivers"}" href="#section-3-class-waivers">Section 3: Class Waivers</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 5" data-track-label="#section-4-compliance-check" data-track-options="{"dimension29":"Section 4: Compliance Check"}" href="#section-4-compliance-check">Section 4: Compliance Check</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 6" data-track-label="#section-5-paediatric-study-plans-psp" data-track-options="{"dimension29":"Section 5: Paediatric Study Plans (PSP)"}" href="#section-5-paediatric-study-plans-psp">Section 5: Paediatric Study Plans (PSP)</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 7" data-track-label="#section-six" data-track-options="{"dimension29":"Section 6: Unmet needs in the UK paediatric population"}" href="#section-six">Section 6: Unmet needs in the UK paediatric population</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 8" data-track-label="#queries-about-paediatric-submissions" data-track-options="{"dimension29":"Queries about paediatric submissions"}" href="#queries-about-paediatric-submissions">Queries about paediatric submissions</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<p>The guidance also covers information for applicants or companies with an agreed <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> opinion conferred prior to 1 January 2021.</p>

<h2 id="general-approach-to-uk-paediatric-investigation-plans">General approach to <abbr title="United Kingdom">UK</abbr> Paediatric Investigation Plans</h2>
<p>We will simplify the <abbr title="Paediatric Investigation Plan">PIP</abbr> application process for applicants by offering an expedited assessment where possible, and by mirroring the submission format and terminology of the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> system. Therefore, the scientific content and assessment required will be kept in line with European Medicines Agency (<abbr title="European Medicines Agency">EMA</abbr>) guidance documents.</p>

<p>Northern Ireland will continue to be part of the <abbr title="European Union">EU</abbr>’s system for paediatric medicines development including agreement of <abbr title="European Union">EU</abbr> paediatric investigation plans (<abbr title="Paediatric Investigation Plans">PIPs</abbr>) or waivers.</p>

<p>We will take decisions on <abbr title="Paediatric Investigation Plan">PIP</abbr> and waiver opinions, modifications and compliance statements to support paediatric market authorisation decisions, while acknowledging that <abbr title="European Union">EU</abbr> <abbr title="Paediatric Investigation Plans">PIPs</abbr> remain applicable for Northern Ireland.</p>

<p><a rel="external" href="https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/2014_c338_01/2014_c338_01_en.pdf" class="govuk-link">Read the European Commission’s principles that the <abbr title="United Kingdom">UK</abbr> will follow</a>.</p>

<p>Paediatric obligations in line with the unfettered access (UA) Great Britain (GB) Marketing Applications will be met by the agreed <abbr title="European Union">EU</abbr> <abbr title="Paediatric Investigation Plan">PIP</abbr> or waiver as required.</p>

<p>The format and submission procedure for <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> applications will be published separately. Applicants should include information relevant specifically to the <abbr title="United Kingdom">UK</abbr>, particularly with respect to any areas of unmet therapeutic need that this product intends to cover in the <abbr title="United Kingdom">UK</abbr> <a href="#section-six" class="govuk-link">[Section 6 of this document]</a>.</p>

<p>This guidance addresses the common scenarios that may occur when a <abbr title="United Kingdom">UK</abbr> paediatric procedure is submitted to the Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>) after 1 January 2021.</p>

<p>A case by case discussion should always be considered for any <abbr title="United Kingdom">UK</abbr> paediatric submissions that do not fall into any of the prespecified criteria listed below.</p>

<p>Further step by step information on the process of submitting <abbr title="Paediatric Investigation Plans">PIPs</abbr> via the new <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> submissions portal will be available in a user reference guide which will be published separately.</p>

<h2 id="section-one">Section 1: <abbr title="Paediatric Investigation Plan">PIP</abbr> submissions</h2>

<h3 id="eu-pip-or-modifications-to-pips-submitted-before-1-january-2021">1.1. <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> or modifications to <abbr title="Paediatric Investigation Plans">PIPs</abbr> submitted before 1 January 2021</h3>

<p><abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>s and modifications agreed by the <abbr title="European Medicines Agency">EMA</abbr> prior to 1 January 2021, will be adopted as <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s on or after that date:</p>

<ul>
  <li>These <abbr title="Paediatric Investigation Plans">PIPs</abbr> will not require re-submission to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>.</li>
</ul>

<p>Where a valid request for an <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> or modification or waiver has been made to the <abbr title="European Medicines Agency">EMA</abbr>, but no decision has been given before 1 January 2021, the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> will be adopted as a <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> if the <abbr title="European Medicines Agency">EMA</abbr> Paediatric Committee (<abbr title="EMA Paediatric Committee">PDCO</abbr>) has given a positive opinion with which the <abbr title="United Kingdom">UK</abbr> has concurred.</p>

<ul>
  <li>These <abbr title="Paediatric Investigation Plans">PIPs</abbr> will not require re-submission to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>.</li>
</ul>

<p>Where a valid request for an <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> or modification or waiver has been made to the <abbr title="European Medicines Agency">EMA</abbr>, but the <abbr title="EMA Paediatric Committee">PDCO</abbr> has issued a negative opinion:</p>

<ul>
  <li>In this case, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will treat the application as refused. However, applicants can submit an updated <abbr title="Paediatric Investigation Plan">PIP</abbr> to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> which addresses the reasons for refusal.</li>
</ul>

<p>Where a valid request for an <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> or modification or waiver has been made to the <abbr title="European Medicines Agency">EMA</abbr>, but the <abbr title="EMA Paediatric Committee">PDCO</abbr> has not yet given any opinion, or where the <abbr title="United Kingdom">UK</abbr> disagreed with the <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion:</p>

<ul>
  <li>These <abbr title="Paediatric Investigation Plans">PIPs</abbr> should be resubmitted to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> unless the applicant notifies <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> that they do not wish the application to proceed.</li>
</ul>

<p><abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>s which become <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s under these transitional provisions will be referred to as adopted <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s in this guidance. New <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> submissions after 1 January 2021 that have been assessed and agreed by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>, will be referred to as agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s.</p>

<h3 id="uk-pip-submissions-after-1-january-2021">1.2. <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> submissions after 1 January 2021</h3>

<p>When a <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> is submitted, information should be provided on whether there is:</p>

<ul>
  <li>an agreed <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> and the opinion and supporting documentation is included</li>
  <li>an ongoing <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> assessment, its timeline in the <abbr title="EMA Paediatric Committee">PDCO</abbr> assessment cycle (i.e. day 30, 60, clock stop, day 90 or 120)</li>
  <li>any scientific divergence between the submitted <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> and the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>
</li>
</ul>

<p>This information will be used to establish the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment process as described in Sections 1.3 to 1.4.</p>

<p>The assessment pathways for <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> submissions from 1 January 2021 are <span id="attachment_4609858" class="attachment-inline"><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/868207/Guidance_on_Procedures_for_UK-PIPs_-Annex.pdf" class="govuk-link">Annexes I and II</a> (<span class="type"><abbr title="Portable Document Format">PDF</abbr></span>, <span class="file-size">90.9KB</span>, <span class="page-length" lang="en">2 pages</span>)</span>.</p>

<h3 id="section-onepointthree">1.3. <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> with agreed <abbr title="European Medicines Agency">EMA</abbr> opinion from 1 January 2021 or ongoing assessment at <abbr title="European Medicines Agency">EMA</abbr> from 1 January 2021</h3>

<p>In principle, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will aim to accept a positive <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion. A focused assessment may be needed considering (but not restricted to) the following:</p>

<ul>
  <li>unmet <abbr title="United Kingdom">UK</abbr> paediatric needs <a href="#section-six" class="govuk-link">[Section 6 of this guidance]</a>;</li>
  <li>paediatric only development particularly for an innovative product (such as a new drug class, mechanism of action)</li>
  <li>the incidence of the disease in the <abbr title="United Kingdom">UK</abbr> population</li>
  <li>the relevance of the scientific arguments by <abbr title="European Medicines Agency">EMA</abbr> / <abbr title="EMA Paediatric Committee">PDCO</abbr> in the summary report (<abbr title="Summary Report">SR</abbr>) to the <abbr title="United Kingdom">UK</abbr> paediatric population</li>
  <li>any additional safety or efficacy concerns for the <abbr title="United Kingdom">UK</abbr> population</li>
  <li>the nature and number of licensed products already available for the intended paediatric indication</li>
  <li>the feasibility of performing the proposed paediatric studies in the <abbr title="United Kingdom">UK</abbr> only</li>
  <li>
<abbr title="Paediatric Investigation Plan">PIP</abbr> is to support a <abbr title="United Kingdom">UK</abbr> Paediatric Use Marketing Authorisation (<abbr title="Paediatric Use Marketing Authorisation">PUMA</abbr>)</li>
</ul>

<p>A full assessment may be requested by the applicant.</p>

<p>If the <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion is negative, the applicant has the option to withdraw the <abbr title="United Kingdom">UK</abbr> <abbr title="Paediatric Investigation Plan">PIP</abbr> or continue with the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment.</p>

<p>If the applicant chooses to continue with the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment despite <abbr title="EMA Paediatric Committee">PDCO</abbr> negative opinion, the applicant should consider incorporating changes to the <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> during clock-stop, for the elements that received a negative <abbr title="EMA Paediatric Committee">PDCO</abbr> assessment.</p>

<p>If a <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> has been withdrawn and a new <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> submitted, the new <abbr title="Paediatric Investigation Plan">PIP</abbr> will undergo review using the same assessment criteria as noted in <a href="#section-one" class="govuk-link">Section 1 of this guidance</a>.</p>

<h3 id="uk-pip-with-no-eu-pip-from-1-january-2021">1.4. <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> with no <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> from 1 January 2021</h3>

<p>Full assessment of the <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> is required.</p>

<p>The applicant should additionally clarify if:</p>

<ul>
  <li>there has been a previous negative <abbr title="European Medicines Agency">EMA</abbr> / <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Paediatric Investigation Plan">PIP</abbr> opinion</li>
  <li>there was a withdrawn <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> prior to the adoption of an <abbr title="European Medicines Agency">EMA</abbr>/<abbr title="EMA Paediatric Committee">PDCO</abbr> opinion</li>
  <li>the current <abbr title="United Kingdom">UK</abbr> submission has been updated since the previous negative or withdrawn <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>
</li>
  <li>the applicant has included the previously withdrawn or negative <abbr title="European Medicines Agency">EMA</abbr> / <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Paediatric Investigation Plan">PIP</abbr> <abbr title="Summary Report">SR</abbr> as part of the supporting documents in the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> submission</li>
  <li>during assessment, consideration will be given to the scientific discussions of the <abbr title="European Medicines Agency">EMA</abbr> / <abbr title="EMA Paediatric Committee">PDCO</abbr> which led to the negative opinion or the withdrawal of the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>
</li>
</ul>

<h2 id="section-2-pip-modifications">Section 2: <abbr title="Paediatric Investigation Plan">PIP</abbr> Modifications</h2>

<h3 id="modification-of-an-adopted-or-agreed-uk-pip">2.1. Modification of an adopted or agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>
</h3>

<p>For both adopted and agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s:</p>

<p>When a <abbr title="Paediatric Investigation Plan">PIP</abbr> modification is submitted, it should be confirmed if there is:</p>

<ul>
  <li>an agreed <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> modification</li>
  <li>an <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> modification assessment ongoing</li>
  <li>the modification submitted is for an adopted or agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>
</li>
  <li>a significant scientific divergence between the current agreed <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> and the agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>
</li>
</ul>

<p>Modifications submitted for <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s where there is an <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr> should include the most recent <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion and <abbr title="Paediatric Investigation Plan">PIP</abbr> <abbr title="Summary Report">SR</abbr>.</p>

<p>For Agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s, there will be either a focused assessment in cases where the <abbr title="European Union">EU</abbr> opinion for the initial <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> was accepted by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> or a full modification assessment in cases where the initial <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> underwent full assessment.</p>

<p>The applicant may request a full assessment.</p>

<h3 id="uk-pip-modification-of-an-agreed-ema-opinion-or-ongoing-assessment-at-ema">2.2. <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> modification of an agreed <abbr title="European Medicines Agency">EMA</abbr> opinion or ongoing assessment at <abbr title="European Medicines Agency">EMA</abbr>
</h3>
<p>In principle, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will aim to accept a positive <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion on modifications in cases where the initial <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> was agreed on the basis of an agreed <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>. A focused assessment may be needed if the criteria in <a href="#section-onepointthree" class="govuk-link">Section 1.3</a> are met.</p>

<p>If the <abbr title="EMA Paediatric Committee">PDCO</abbr> opinion is negative whilst the <abbr title="United Kingdom">UK</abbr> assessment is ongoing:</p>

<ul>
  <li>The applicant has the option to withdraw the <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> modification request or continue with the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment</li>
  <li>Once a <abbr title="Paediatric Investigation Plan">PIP</abbr> has been withdrawn, a new <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> modification can be submitted and will undergo review using the same assessment criteria discussed in <a href="#section-onepointthree" class="govuk-link">Section 1.3 of this guidance</a>
</li>
  <li>If continuing with the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment, the applicant can discuss amendments to the proposals before the final <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> opinion on the proposed Modification is agreed</li>
</ul>

<h3 id="uk-pip-modification-with-no-agreed-eu-pip-modification">2.3. <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> modification with no agreed <abbr title="European Union">EU</abbr> <abbr title="Paediatric Investigation Plan">PIP</abbr> modification</h3>
<p>If there is no agreed <abbr title="European Medicines Agency">EMA</abbr> modification opinion a full assessment of modification will be required.</p>

<h2 id="section-3-class-waivers">Section 3: Class Waivers</h2>

<h3 id="submission-of-paediatric-class-waiver">3.1. Submission of Paediatric Class Waiver</h3>

<p>The current <abbr title="European Medicines Agency">EMA</abbr> class waivers list will be adopted by the <abbr title="United Kingdom">UK</abbr> from 1 January 2021.</p>

<p>In principle, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will aim to accept a positive <abbr title="European Medicines Agency">EMA</abbr> opinion on a class waiver request. Where there is no <abbr title="European Medicines Agency">EMA</abbr> opinion, a <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment will be undertaken.</p>

<p>For a negative <abbr title="European Medicines Agency">EMA</abbr> opinion on whether a Class Waiver applies:</p>

<ul>
  <li>the applicant should submit a full product specific waiver request for <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment which should include <abbr title="European Medicines Agency">EMA</abbr> opinion on the class waiver</li>
  <li>if there is an <abbr title="European Medicines Agency">EMA</abbr> opinion on the applicant’s subsequent product specific waiver request, then this should be made available to determine if a focused or full assessment is required</li>
</ul>

<h2 id="section-4-compliance-check">Section 4: Compliance Check</h2>

<h3 id="section-fourpointone">4.1. Adopted <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> Compliance check (<abbr title="Compliance Check">CC</abbr>)</h3>

<p>A positive <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Compliance Check">CC</abbr> or interim <abbr title="Compliance Check">CC</abbr> will be adopted as the <abbr title="United Kingdom">UK</abbr> <abbr title="Compliance Check">CC</abbr> outcome unless subsequent modifications have led to divergence between the <abbr title="United Kingdom">UK</abbr>- and <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>s.</p>

<p>However, the applicant must pay particular attention to the agreed timelines of those measures which would need to be completed after the <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Compliance Check">CC</abbr> to ensure compliance on the date of the <abbr title="United Kingdom">UK</abbr> Marketing Authorisation (<abbr title="Marketing Authorisations">MA</abbr>) submission.</p>

<p>The <abbr title="EMA Paediatric Committee">PDCO</abbr> compliance outcome documents should be submitted ahead of, or at the time of <abbr title="Marketing Authorisations">MA</abbr> application. The format and submission procedure for <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> applications will be published separately.</p>

<h3 id="agreed-uk-pip-cc">4.2. Agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> <abbr title="Compliance Check">CC</abbr>
</h3>

<p>A <abbr title="United Kingdom">UK</abbr> assessment is required for full or interim <abbr title="Compliance Check">CC</abbr> if:</p>

<ul>
  <li>there is any scientific divergence between the agreed <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> and the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>
</li>
  <li>there is no <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Compliance Check">CC</abbr>
</li>
</ul>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will adopt the <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Compliance Check">CC</abbr> outcome if:</p>

<ul>
  <li>there is a positive <abbr title="EMA Paediatric Committee">PDCO</abbr> <abbr title="Compliance Check">CC</abbr>
</li>
  <li>the <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> is equivalent to the <abbr title="EU Paediatric Investigation Plan">EU-PIP</abbr>
</li>
</ul>

<p>Applicants are encouraged to request a <abbr title="Compliance Check">CC</abbr> ahead of submission of an <abbr title="Marketing Authorisations">MA</abbr> application where one is required for validation. At completion of the <abbr title="Compliance Check">CC</abbr> procedure, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will issue compliance outcome documents similar to those noted in <a href="#section-fourpointone" class="govuk-link">Section 4.1</a> above.</p>

<h3 id="non-compliance">4.3. Non-Compliance</h3>

<ul>
  <li>For non-compliance due to (minor) administrative issues, or discrepancies that do not affect the scientific conduct of the study, a streamlined assessment will be proposed at the time the applicant is informed of the noncompliance outcome</li>
  <li>This streamlined assessment will combine a shortened modification procedure with a rapid <abbr title="Compliance Check">CC</abbr>
</li>
  <li>If the above is not applicable, the applicant will be required to submit a modification for a full assessment to align the non-compliant key elements of the opinion with those of the completed study report</li>
  <li>A rapid <abbr title="Compliance Check">CC</abbr> will be offered at the end of a positive modification agreement</li>
</ul>

<h3 id="statements-of-compliance">4.4. Statements of compliance</h3>

<p>An <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> statement of compliance when all of the agreed <abbr title="Paediatric Investigation Plan">PIP</abbr> measures have been completed, will be issued, if appropriate, when an <abbr title="Marketing Authorisations">MA</abbr> application (initial, extension or variation) is granted:</p>

<p>The development of this product has complied with all measures in the agreed paediatric investigation plan < reference number >.</p>

<p>The Summary of Product Characteristics and, where applicable, the package leaflet will include the results of the studies referred to in the <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>.</p>

<h2 id="section-5-paediatric-study-plans-psp">Section 5: Paediatric Study Plans (<abbr title="Paediatric Study Plans">PSP</abbr>)</h2>

<h3 id="paediatric-study-plans-psp">5.1. Paediatric study plans (<abbr title="Paediatric Study Plans">PSP</abbr>)</h3>

<p>Regarding the applicant’s paediatric study plans (<abbr title="Paediatric Study Plans">PSP</abbr>) agreed by the US Food and Drug Administration (<abbr title="Food and Drug Administration">FDA</abbr>):</p>

<ul>
  <li>Applicants should provide the agreed <abbr title="Paediatric Study Plans">PSP</abbr> as part of their <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr> submission</li>
</ul>

<h2 id="section-six">Section 6: Unmet needs in the <abbr title="United Kingdom">UK</abbr> paediatric population</h2>

<p>The unmet needs for the <abbr title="United Kingdom">UK</abbr> paediatric population will be defined by:</p>

<ul>
  <li>therapeutic areas identified by <abbr title="United Kingdom">UK</abbr> health bodies as high priority public health concerns</li>
  <li>product development in conditions identified after consultations with <abbr title="United Kingdom">UK</abbr> experts and patient groups, including those for rare diseases identified under the auspices of the Department of Health and Social Care (<abbr title="Department of Health and Social Care">DHSC</abbr>) policy paper - <a rel="external" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_Rare_Diseases.pdf" class="govuk-link"><abbr title="United Kingdom">UK</abbr> strategy for rare diseases</a>
</li>
  <li>product development in conditions (or paediatric groups) identified as critically important in the <a rel="external" href="https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf" class="govuk-link">Paediatric Regulation 10 year report</a>
</li>
  <li>products which are intended to be authorised as orphan medicines.</li>
</ul>

<p>This guidance will apply from 1 January 2021 in line with the  <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made" class="govuk-link">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

<p>The legal requirements for <abbr title="UK Paediatric Investigation Plan">UK-PIP</abbr>s are set out in the Human Medicines Regulations 2012, as amended by the  <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made" class="govuk-link">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a> (<abbr title="Human Medicines Regulations">HMRs</abbr>), including transitional provisions.</p>

<h2 id="queries-about-paediatric-submissions">Queries about paediatric submissions</h2>

<p>For general enquiries about paediatric submissions including <abbr title="Paediatric Investigation Plan">PIP</abbr> and waiver applications, modification procedures, and compliance checks, contact the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> Paediatric Unit at <a href="mailto:ukpip@mhra.gov.uk" class="govuk-link">ukpip@mhra.gov.uk</a>.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 1 September 2020
    <br></br>Last updated 27 October 2020
      <a href="#full-history" class="app-c-published-dates__toggle govuk-link" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-10-27T09:00:01.000+00:00">27 October 2020</time>
              <p class="app-c-published-dates__change-note">New information around Northern Ireland has been added in the section on 'General approach to UK Paediatric Investigation Plans'</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-09-01T15:01:00.000+01:00">1 September 2020</time>
              <p class="app-c-published-dates__change-note">First published.</p>
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-60e1c27a" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-60e1c27a" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/guidance/completed-paediatric-studies-submission-processing-and-assessment-from-1-january-2021" data-track-options="{"dimension28":"5","dimension29":"Completed Paediatric Studies - submission, processing and assessment from 1 January 2021"}" href="/guidance/completed-paediatric-studies-submission-processing-and-assessment-from-1-january-2021">Completed Paediatric Studies - submission, processing and assessment from 1 January 2021</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.2 Related content" data-track-label="/government/publications/format-and-content-of-applications-for-agreement-or-modification-of-a-paediatric-investigation-plan-and-requests-for-waivers-or-deferrals-and-concerni" data-track-options="{"dimension28":"5","dimension29":"Format and content of applications for agreement or modification of a Paediatric Investigation Plan and requests for waivers or deferrals and concerning the operation of the compliance check from 1 January 2021"}" href="/government/publications/format-and-content-of-applications-for-agreement-or-modification-of-a-paediatric-investigation-plan-and-requests-for-waivers-or-deferrals-and-concerni">Format and content of applications for agreement or modification of a Paediatric Investigation Plan and requests for waivers or deferrals and concerning the operation of the compliance check from 1 January 2021</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.3 Related content" data-track-label="/guidance/reference-medicinal-products-rmps-from-1-january-2021" data-track-options="{"dimension28":"5","dimension29":"Reference Medicinal Products (RMPs) from 1 January 2021"}" href="/guidance/reference-medicinal-products-rmps-from-1-january-2021">Reference Medicinal Products (RMPs) from 1 January 2021</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.4 Related content" data-track-label="/guidance/guidance-on-qualified-person-responsible-for-pharmacovigilance-qppv-including-pharmacovigilance-system-master-files-psmf-from-1-january-2021" data-track-options="{"dimension28":"5","dimension29":"Guidance on qualified person responsible for pharmacovigilance (QPPV) including pharmacovigilance system master files (PSMF) from 1 January 2021"}" href="/guidance/guidance-on-qualified-person-responsible-for-pharmacovigilance-qppv-including-pharmacovigilance-system-master-files-psmf-from-1-january-2021">Guidance on qualified person responsible for pharmacovigilance (QPPV) including pharmacovigilance system master files (PSMF) from 1 January 2021</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar gem-c-related-navigation__section-link--inline  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.5 Related content" data-track-label="/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-from-1-january-2021" data-track-options="{"dimension28":"5","dimension29":"Comparator products in Bioequivalence/Therapeutic Equivalence studies from 1 January 2021"}" href="/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-from-1-january-2021">Comparator products in Bioequivalence/Therapeutic Equivalence studies from 1 January 2021</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-60e1c27a" data-module="gem-toggle">

    <h3 id="related-nav-collections-60e1c27a" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-6d2e0e8b" data-module="gem-toggle">

    <h2 id="related-nav-topics-6d2e0e8b" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/clinical-trials-investigations" data-track-options="{"dimension28":"2","dimension29":"Clinical trials and investigations"}" href="/topic/medicines-medical-devices-blood/clinical-trials-investigations">Clinical trials and investigations</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"2","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>